DexCom Gelecekteki Büyüme

Future kriter kontrolleri 4/6

DexCom kazanç ve gelirin sırasıyla yıllık 16.8% ve 13.4% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 16.1% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 26.8% olacağı tahmin edilmektedir.

Anahtar bilgiler

16.8%

Kazanç büyüme oranı

16.1%

EPS büyüme oranı

Medical Equipment kazanç büyümesi	18.6%
Gelir büyüme oranı	13.4%
Gelecekteki özkaynak getirisi	26.8%
Analist kapsamı	Good
Son güncelleme	29 Oct 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

BOVESPA:D1EX34 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	5,317	956	1,010	1,384	21
12/31/2025	4,604	783	801	1,139	24
12/31/2024	4,016	636	609	945	24
9/30/2024	3,954	681	535	822	N/A
6/30/2024	3,935	667	666	891	N/A
3/31/2024	3,802	639	584	802	N/A
12/31/2023	3,622	542	512	749	N/A
9/30/2023	3,403	377	500	747	N/A
6/30/2023	3,198	358	466	771	N/A
3/31/2023	3,023	293	416	754	N/A
12/31/2022	2,910	341	305	670	N/A
9/30/2022	2,793	244	261	643	N/A
6/30/2022	2,673	230	216	597	N/A
3/31/2022	2,572	258	95	486	N/A
12/31/2021	2,449	217	53	443	N/A
9/30/2021	2,319	577	140	509	N/A
6/30/2021	2,170	562	101	409	N/A
3/31/2021	2,027	530	236	502	N/A
12/31/2020	1,927	550	277	476	N/A
9/30/2020	1,821	231	264	447	N/A
6/30/2020	1,716	205	209	394	N/A
3/31/2020	1,601	148	131	305	N/A
12/31/2019	1,476	101	135	315	N/A
9/30/2019	1,351	-171	51	205	N/A
6/30/2019	1,222	-170	39	167	N/A
3/31/2019	1,128	-130	53	144	N/A
12/31/2018	1,032	-127	56	123	N/A
9/30/2018	915	43	64	131	N/A
6/30/2018	833	-5	N/A	110	N/A
3/31/2018	761	-33	N/A	83	N/A
12/31/2017	719	-50	N/A	92	N/A
9/30/2017	669	-48	N/A	64	N/A
6/30/2017	633	-65	N/A	51	N/A
3/31/2017	599	-88	N/A	57	N/A
12/31/2016	573	-66	N/A	56	N/A
9/30/2016	533	-57	N/A	54	N/A
6/30/2016	490	-80	N/A	49	N/A
3/31/2016	445	-64	N/A	45	N/A
12/31/2015	402	-58	N/A	49	N/A
9/30/2015	356	-58	N/A	46	N/A
6/30/2015	319	-20	N/A	40	N/A
3/31/2015	285	-23	N/A	29	N/A
12/31/2014	259	-22	N/A	24	N/A
9/30/2014	227	-26	N/A	20	N/A
6/30/2014	201	-27	N/A	10	N/A
3/31/2014	178	-31	N/A	5	N/A
12/31/2013	160	-30	N/A	2	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: D1EX34 'nin tahmini kazanç büyümesi (yıllık 16.8% ) tasarruf oranının ( 10.1% ) üzerindedir.

Kazançlar ve Piyasa: D1EX34 şirketinin kazançlarının (yıllık 16.8% ) BR pazarından (yıllık 13.3% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: D1EX34 şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: D1EX34 şirketinin gelirinin (yıllık 13.4% ) BR pazarından (yıllık 7.6% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: D1EX34 şirketinin gelirinin (yıllık 13.4% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: D1EX34 'in Özsermaye Getirisi'nin 3 yıl içinde yüksek olması tahmin ediliyor ( 26.8 %)

DexCom Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

DexCom, Inc. Reiterates Earnings Guidance for the Fiscal Year 2024

DexCom, Inc. Updates Earnings Guidance for the Year 2024

DexCom, Inc. Provides Earnings Guidance for the Year 2024

DexCom, Inc. Reiterates Revenue Guidance for the Fiscal Year 2024

Dexcom, Inc. Provides Revenue Guidance for the Full Year of 2024

DexCom, Inc. Increases Earnings Guidance for the Fiscal Year 2023

Recent updates

DexCom, Inc. Reiterates Earnings Guidance for the Fiscal Year 2024

Kessler Topaz Meltzer & Check, LLP Files Class Action Lawsuit Against Dexcom, Inc

DexCom, Inc. to Showcase Transformational Impact of Dexcom CGM Technology at the EASD 2024 Conference Symposium

Stelo by Dexcom, the First Over-The-Counter Glucose Biosensor in the U.S., Is Now Available

Levi & Korsinsky, LLP Files Complaint to Recover Losses Suffered by Purchasers of DexCom, Inc

DexCom, Inc. Updates Earnings Guidance for the Year 2024

DexCom, Inc. to Report Q2, 2024 Results on Jul 25, 2024

Dexcom Showcases Extensive Clinical Data At ADA 2024 Demonstrating the Benefit of Dexcom CGM Use Among People with Type 2 Diabetes

Dexcom, Inc. Announces the Dexcom G7 Continuous Glucose Monitoring System Now Connects Directly to Apple Watch in the United States

Dexcom Wins Access to Dexcom One for 100,000 People Living with Type 2 Diabetes

DexCom, Inc. Provides Earnings Guidance for the Year 2024

DexCom, Inc., Annual General Meeting, May 22, 2024

DexCom, Inc., Annual General Meeting, May 22, 2024

DexCom, Inc. to Report Q1, 2024 Results on Apr 25, 2024

DexCom, Inc. Announces the FDA Clears Stelo by Dexcom – the First Glucose Biosensor

DexCom, Inc. Reiterates Revenue Guidance for the Fiscal Year 2024

DexCom, Inc. Launches Dexcom One+ Bringing Powerful, New Diabetes Management Technology to More People

Dexcom, Inc. Announces the Dexcom G7 Continuous Glucose Monitoring System Now Connects with the t:Slim X2™ Insulin Pump by Tandem Diabetes Care in Countries Across Europe and in South Africa

DexCom, Inc. to Report Q4, 2023 Results on Feb 08, 2024

Dexcom, Inc. Provides Revenue Guidance for the Full Year of 2024

Dexcom, Inc. Announces the Dexcom G7 Continuous Glucose Monitoring System Now Connects with the Tandem t:slim X2 Insulin Pump

DexCom, Inc. (NasdaqGS:DXCM) announces an Equity Buyback for $500 million worth of its shares.

Dexcom Solidifies Global Leadership in Continuous Glucose Monitoring with New Clinical Data Presented at EASD

DexCom, Inc. to Report Q3, 2023 Results on Oct 26, 2023

DexCom, Inc Announces the Availability of Its Dexcom One Real-Time CGM Sensor Via Reimbursement, in France

DexCom, Inc. Announces Appointment of Rimma Driscoll to Its Board of Directors

DexCom, Inc. Increases Earnings Guidance for the Fiscal Year 2023

DexCom, Inc. to Report Q2, 2023 Results on Jul 27, 2023

Dexcom, Inc. Receives Health Canada Approval: Next-Generation Continuous Glucose Monitoring System with Unmatched Accuracy Coming to Canadians

DexCom, Inc. Updates Earnings Guidance for the Year 2025

DexCom, Inc. Reiterates Revenue Guidance for the Fiscal Year 2023

Dexcom, Inc.'s G6 Real-Time CGM System Now Available to All Clients With Type 1 Diabetes Covered Under the Non-Insured Health Benefits Program

DexCom, Inc. to Report Q4, 2022 Results on Feb 09, 2023

Dexcom, Inc. Receives FDA Clearance of Next-Generation Dexcom G7 Continuous Glucose Monitoring System

DexCom, Inc. Provides Earnings Guidance for the Year 2022

DexCom, Inc. Announces the Launch of Dexcom U

DexCom, Inc. Announces Launch of Dexcom G7 in the United Kingdom, Ireland, Germany, Austria and Hong Kong – Initiating Global Rollout of World’s Most Powerful Continuous Glucose Monitoring System

DexCom, Inc. to Report Q3, 2022 Results on Oct 27, 2022

DexCom, Inc. Promotes Jacob S. Leach to Chief Operating Officer

DexCom, Inc. Announces One Real-Time Continuous Glucose Monitoring (rt-CGM) System Available on Prescription in the UK

DexCom, Inc. (NasdaqGS:DXCM) announces an Equity Buyback for $700 million worth of its shares.

DexCom, Inc. Revises Earnings Guidance for the Full Year 2022

DexCom, Inc. Announces Resignation of Chad M. Patterson as Executive Vice President, Global Marketing, Effective July 15, 2022

DexCom, Inc. to Report Q2, 2022 Results on Jul 28, 2022

Dexcom Says Not in Active Merger Talks

Dexcom Reportedly in Talks to Acquire Insulet

DexCom, Inc. Showcases Expanded CGM Portfolio at International ATTD Conference

Dexcom Announces Dexcom ONE, the Newest Real-Time Continuous Glucose Monitoring System, to Its Range of Scan-Free and Fingerprick†-Free Devices

DexCom, Inc. to Report Q1, 2022 Results on Apr 28, 2022

DexCom, Inc. Reiterates Earnings Guidance for the Fiscal Year 2022

Dexcom, Inc. Reports Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Fiscal Year Ended December 31, 2021; Revenue Guidance for the Fiscal Year 2022

Dexcom G6 Continuous Glucose Monitoring System Now Covered in Manitoba for Young People with Type 1 Diabetes

Dexcom, Inc. Announces Non-insured Health Benefits Program Covers Dexcom G6 Continuous Glucose Monitoring System for Children and Adolescents on Intensive Insulin Therapy

FDA Clears DexCom, Inc.'s Real-Time APIs for Third-Party Apps and Devices

DexCom, Inc.(NasdaqGS:DXCM) dropped from Russell Top 200 Index

DexCom, Inc. Announces Results of Two New Studies Illustrate Continued Momentum for Dexcom CGM, Including JAMA-Published Data on Additional Populations Who Can Benefit from the Technology

DexCom, Inc. (NasdaqGS:DXCM) acquired assets in the Netherlands, Belgium and Luxembourg from a Dexcom distributor.

DexCom, Inc. Increasing Revenue Guidance for Fiscal Year 2021

DexCom, Inc. Announces Launch of Dexcom Ventures

Everside Health's Legacy Healthstat Partners with Dexcom to Provide Continuous Glucose Monitoring for Type 2 Diabetes

DexCom, Inc. to Report Q4, 2020 Results on Feb 11, 2021

DexCom, Inc. Revises Revenue Guidance for Fiscal Year 2020

DexCom Announces Retirement of Rick Doubleday as Executive Vice President and Chief Commercial Officer

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin